The Way Forward Dr David Simpson
New therapeutic agents in myeloma 2003 2006 2009 2012 2015 2018 Future Bortezomib Thalidomide Lenalidomide Carfilzomib Panobinostat Pharmac Funded Ixazomib Pomalidomide Elotuzumab FDA approved Daratumumab Isatuximab Selinexor Anti-BCMA Venetoclax In pipeline CAR-T
Better outcomes in myeloma What we want What we have How do you bridge the gap Carfilzomib Pharmac Venetoclax Velcade Daratumumab Thalidomide Isatuximab Cyclophosphamide Anti-BCMA Dexamethasone Pomalidomide Lenalidomide More lenalidomide
Curing Myeloma – We need good drugs early
Cancer drugs outstrip wages…
How much do we spend on drugs? USD PPP Annual/Capita Drug Spend 800 700 NZ 600 500 400 300 200 100 0 2010 2011 2012 2013 2014 2015 2016 2017 Data extracted on 23 Mar 2019 05:00 UTC (GMT) from OECD.Stat
Life-cycle of drug costs Pharmac Compassion Phase 1 Phase 2 Phase 3 Brand Generic Access Drug $100K Research $0 $100K Years
Collect real world data Unique NHI Global Pricing Pharmac Pharma
Solutions More money for Pharmac Simplify and streamline cancer intervention trials Pharmac to work with Pharma to obtain “real world” data on treatment outcomes to offset new drug costs
Recommend
More recommend
